FDA Chief Of Staff Barclay Hails From Agency, By Way Of M Street
This article was originally published in The Pink Sheet Daily
Executive Summary
Lisa Barclay returns to government from Zuckerman Spaeder where she co-authored a report urging more regulation of nutritional supplements based on nanotechnology.
You may also be interested in...
People In The News: Tracking The Latest Industry Personnel Moves
Don Berwick steps down as CMS chief; new leadership at BIO Ventures for Global Health; former Pfizer CEO Kindler joins two boards of directors; more personnel announcements in this month’s column.
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the drug and biologic review centers intact but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
Nanotech Growth Means Shrinking Window For Enacting Effective Regulation
Ground rules on regulating the use of nanoscale materials in dietary supplements and other consumer products are urgently needed with the nascent technology exploding in the marketplace, a former FDA executive says